An interim phase 1/2 trial update found that DB107-RRV plus DB107-FC could be given in combination with radiation in newly diagnosed high-grade glioma.
Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.